Huadao Biologics Completes RMB 100 Million Series B Financing to Advance Full-Chain CAR-T Innovation and Files IPO Prospectus

Recently, HuaDao (Shanghai) BiopharmaceuticalPharmaceuticalsHuaDao CAR-Tcell (hereinafter referred to as “HuaDao Bio”) has officially completed a RMB 100 million Series B strategic financing round. This round was led by Boai NKY Medical Holdings Ltd. (hereinafter referred to as “NKY,” stock code: 300109), with follow-on investment from Mr. Ren Dalong, Deputy General Manager of NKY. The proceeds will be utilized for the research and development of cell-based (CAR-T) therapies and technological innovation in the industrialization of cell-based (CAR-T) products, thereby propelling HuaDao Bio to become China’s first autonomous, platform-oriented “intelligent manufacturing” pharmaceutical enterprise integrating biotechnology, medical technology, pharmaceutical technology, automated intelligent preparation technology, and network operational technology across the entire CAR-T industry value chain.

Mr. Ren Dalong, Deputy General Manager of Boai NKY Medical Holdings Ltd., stated that the National Health Commission’s release in March of this year of the “Administrative Measures for Clinical Research and Translational Application of Somatic Cell Therapy (Trial) (Draft for Comments)” further validates the rationality of our assessment of the cell therapy (CAR-T) industry. HuaDao CAR-Tcell has emerged as my investment target primarily based on the following three criteria: 1. The founder, Mr. Yu Xuejun, has pursued a path of independent innovation aimed at industrialization, committing to “developing CAR-T cell therapies affordable to the Chinese public,” which demonstrates his profound and keen insight into the industry. I strongly endorse the company’s orientation toward becoming a platform-based enterprise with a differentiated strategy; for a company heading in the right direction, success is merely a matter of time; 2. HuaDao CAR-Tcell’s technological innovations in the industrialization of CAR-T cell therapy are not mere slogans; the company has conducted extensive and rigorous research, achieving substantial results, which demonstrates its capability to “do the right things correctly”; 3. Against a backdrop of complex and volatile uncertainties, the HuaDao CAR-Tcell team has remained true to its original mission despite crises. Their cohesive spirit in facing difficulties and their combat-ready execution in resolving challenges constitute valuable assets for the company’s continuous development. I am highly confident in the future of HuaDao CAR-Tcell.

Mr. Wang Jianqiang, Vice Chairman of Boai NKY Medical Holdings Ltd., stated that this investment serves as a crucial support for the company’s dual-platform strategy of building “consumer specialty chemicals” and “healthcare medical services.” Therefore, this is not a one-time transaction but a long-term, continuous strategic “investment.” It represents an “investment” characterized by the synergy of industry-research integration, industry-medical integration, and industry-finance combination, achieving a “1+1>2” effect. It involves multi-level, multi-channel, multi-form, three-dimensional, and all-around cooperation across R&D, production, marketing, resources, the medical industry chain, and capital.The confidence and foundation for this cooperation stem from the following:1. Shared values are the cornerstone of cooperation: HuaDao CAR-Tcell’s path of independent innovation and its mission to “make cell therapies affordable for the Chinese people” align perfectly with Boai NKY’s corporate spirit of “innovation like a newly sharpened blade, creating value through practical application, and sustaining long-term growth.” In this new era, on this new journey, with new missions and actions, we must possess confidence, responsibility, accountability, and capability.2. The synergistic complementarity between Boai NKY and HuaDao CAR-Tcell in areas such as industry-medical integration and industry-research integration is the driving force behind our deep cooperation:(1) The HuaDao CAR-T Cell Industry Technology Innovation Center (Songjiang) base project is a key component of Boai NKY’s long-term layout in precision diagnostics and precision medical services. It will play a long-term leading and promoting role in the construction, development, and upgrading of Boai NKY’s precision medicine brand.(2) Technological innovation in the cell (CAR-T) industry involves the entire industrial chain; it is a systematic, long-term, comprehensive engineering endeavor that cannot be accomplished by any single institution alone. The deep, intertwined cooperation among various projects—such as the localization of key reagents for cell (CAR-T) industrialization at Boai NKY’s Songjiang base (undertaken by BioVision, Inc., USA), the nationwide network of Boai NKY Precision Medicine Studios (managed by Beijing Precision Medicine Technology Co., Ltd.), and the construction of the HuaDao CAR-T Cell Industry Technology Innovation Center (Songjiang) base (managed by Shanghai Boai NKY Biotechnology Co., Ltd.)—will provide robust and long-term support for HuaDao CAR-Tcell in developing accessible, hard-core CAR-T technologies.3. “A successful mission is one that benefits all participants” is our shared vision. These participants should also include “patients.” We look forward to more partners joining us in the mission to innovate across the entire cell (CAR-T) industry chain, helping HuaDao CAR-Tcell become a leader in technological innovation within the sector, thereby benefiting the general public and creating a better life.

“This collaboration is of great significance to the future development of HuaDao CAR-Tcell. On the resource platform established by Boai NKY, the HuaDao CAR-Tcell Industrial Technology Innovation Center (Songjiang) Base Project will be a key priority construction project within Boai NKY’s Songjiang production base. This initiative is poised to facilitate HuaDao CAR-Tcell’s transformation from a developer of full-industry-chain production technologies for cell (CAR-T) industrialization into a service provider. In particular, market integration with the resources of the Boai NKY Precision Diagnosis and Treatment Center Platform will accelerate the conversion of HuaDao’s cell (CAR-T) research products into tangible productive forces, thereby promoting the integrated upgrading of ‘industry, academia, research, and application’,” stated Yu Xuejun, Chairman of HuaDao CAR-Tcell. He emphasized that the cell (CAR-T) industry represents a strategic high ground in global competition among emerging industries. The core hard technology enabling China’s cell (CAR-T) industry to achieve overtaking on bends lies in “achieving independent intellectual property rights for intelligent manufacturing and full-industry-chain production preparation technologies of CAR-T cells, breaking dependence on foreign production and preparation technologies, reducing the cost of cell (CAR-T) industrialization to its minimum, and ultimately realizing autonomous pricing power.” The core mission of the HuaDao CAR-Tcell Industrial Technology Innovation Center (Songjiang) Base Project is to implement critical bottleneck production technologies for cell (CAR-T) industrialization, creating China’s first fully independently owned intellectual property platform for cell (CAR-T) industry translation and production technology. This will accelerate the industrialization, scaling, and branding of intelligent manufacturing in China’s cell (CAR-T) sector, making cell (CAR-T) therapies accessible medications that benefit a broad population of cancer patients.